Table 4.

Outcomes From the CombAT Study

Outcomes at 48 Months		Mean Change
	Dutasteride	Tamsulosin	Dutasteride+
	(n = 1623)	(n = 1611)	Tamsulosin
			(n = 1610)
Δ IPSS	−5.3	−3.8	−6.3
% Patients Δ IPSS ≥ 25%	61	52	67
Δ PFR (mL/s)	2.0	0.7	2.4
Progression Events		Number (%) Events
Symptoms	212 (13.1)	229 (14.2)	139 (8.6)
AUR	37 (2.3)	82 (5.1)	26 (1.6)
BPH surgery	56 (3.5)	126 (7.8)	38 (2.4)
Incontinence	60 (3.7)	65 (4.0)	49 (3.0)
UTI	5 (0.3)	5 (0.3)	3 (0.2)
Renal insufficiency	2 (0.1)	7 (0.4)	1 (< 0.1)

AUR, acute urinary retention; BPH, benign prostatic hyperplasia; CombAT, Combination of Avodart and Tamsulosin; IPSS, International Prostate Symptom Score; PFR, peak flow rate; UTI, urinary tract infection. Data from Roehrborn CG et al.¹⁵